1. Home
  2. RGT vs ACRV Comparison

RGT vs ACRV Comparison

Compare RGT & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Royce Global Value Trust Inc.

RGT

Royce Global Value Trust Inc.

HOLD

Current Price

$14.45

Market Cap

94.4M

Sector

Finance

ML Signal

HOLD

Logo Acrivon Therapeutics Inc.

ACRV

Acrivon Therapeutics Inc.

HOLD

Current Price

$1.48

Market Cap

82.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RGT
ACRV
Founded
1986
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
94.4M
82.2M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
RGT
ACRV
Price
$14.45
$1.48
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$11.67
AVG Volume (30 Days)
11.7K
408.5K
Earning Date
01-01-0001
05-08-2026
Dividend Yield
1.43%
N/A
EPS Growth
N/A
15.13
EPS
0.92
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$568.17
P/E Ratio
$15.58
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.62
$1.15
52 Week High
$14.99
$3.56

Technical Indicators

Market Signals
Indicator
RGT
ACRV
Relative Strength Index (RSI) 57.48 41.40
Support Level $13.95 $1.46
Resistance Level $14.83 $2.22
Average True Range (ATR) 0.27 0.09
MACD 0.01 -0.01
Stochastic Oscillator 63.41 32.18

Price Performance

Historical Comparison
RGT
ACRV

About RGT Royce Global Value Trust Inc.

Royce Global Value Trust Inc is a diversified closed-end investment company. The Fund spreads its investments across diversified sectors such as information technology, consumer discretionary, health care, materials, consumer staples and energy. Geographically, it has presence in the United Kingdom, Japan, the United States, Canada, France, Hong Kong and Germany.

About ACRV Acrivon Therapeutics Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.

Share on Social Networks: